NR4A1 and neoplasm: A Prospective, Randomized, Multicenter Trial in Italy with aged 55- 75 years, tumor up to 2.5 cm, 0–3 positive axillary lymph nodes, regardless of hormonal-receptor status and tumor grade, were randomly assigned to BCS + RT or BCS alone.